PK, immunogenicity, and antitumor activity will also be evaluated. The study is currently enrolling at sites in the US, with future enrollment in China planned.

7 months ago

Clinical • P1/2 data • Metastases

CD70 (CD70 Molecule)

PRO1160

11ms

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (KCRS 2023)

No abstract available

11 months ago

Clinical • P1/2 data • Metastases

CD70 (CD70 Molecule)

PRO1160

2years

PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma (AACR 2022)

PRO1160 has the potential for an expanded therapeutic index. PRO1160 is being developed for the potential treatment of patients with CD70-expressing hematologic and solid tumor cancers.

2 years ago

Preclinical

CD70 (CD70 Molecule)

CD70 expression

PRO1160